Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zibotentan + dapagliflozin versus dapagliflozin in chronic kidney disease with high proteinuria
NL-OMON58749Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of zibotentan and dapagliflozin in chronic kidney disease (CKD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Change in eGFR from baseline to Month 24. Started Apr 2024; status: active, not recruiting.
02
Drugs
zibotentandapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON58749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58749.